444 related articles for article (PubMed ID: 28789495)
21. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
[TBL] [Abstract][Full Text] [Related]
22. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
[TBL] [Abstract][Full Text] [Related]
23. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
24. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
[TBL] [Abstract][Full Text] [Related]
25. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.
Voso MT; Niscola P; Piciocchi A; Fianchi L; Maurillo L; Musto P; Pagano L; Mansueto G; Criscuolo M; Aloe-Spiriti MA; Buccisano F; Venditti A; Tendas A; Piccioni AL; Zini G; Latagliata R; Filardi N; Fragasso A; Fenu S; Breccia M;
Eur J Haematol; 2016 Apr; 96(4):344-51. PubMed ID: 26018238
[TBL] [Abstract][Full Text] [Related]
26. [High Risk Factors for Transformation into Acute myeloid Leukemia in Patients with Intermediate and High Risk Myelodysplastic syndrome].
Yang Q; Nie SM; Li TL; Huang JX; Liu SS; Gao Y; Yan XS; Mao CX; Meng FJ; Feng XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):558-566. PubMed ID: 32319396
[TBL] [Abstract][Full Text] [Related]
27. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.
Ritchie EK; Feldman EJ; Christos PJ; Rohan SD; Lagassa CB; Ippoliti C; Scandura JM; Carlson K; Roboz GJ
Leuk Lymphoma; 2013 Sep; 54(9):2003-7. PubMed ID: 23270581
[TBL] [Abstract][Full Text] [Related]
28. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.
Garcia-Manero G; Jabbour E; Borthakur G; Faderl S; Estrov Z; Yang H; Maddipoti S; Godley LA; Gabrail N; Berdeja JG; Nadeem A; Kassalow L; Kantarjian H
J Clin Oncol; 2013 Jul; 31(20):2548-53. PubMed ID: 23733767
[TBL] [Abstract][Full Text] [Related]
29. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen].
Wu M; Ma IX; Xie YH; Ye XJ; He HS; Hua JS; Yang RY; Wang XH; Wang XQ; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1991-1997. PubMed ID: 33283731
[TBL] [Abstract][Full Text] [Related]
31. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
32. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Kantarjian HM; O'Brien S; Huang X; Garcia-Manero G; Ravandi F; Cortes J; Shan J; Davisson J; Bueso-Ramos CE; Issa JP
Cancer; 2007 Mar; 109(6):1133-7. PubMed ID: 17315156
[TBL] [Abstract][Full Text] [Related]
33. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Daver N; Kantarjian H; Garcia-Manero G; Jabbour E; Borthakur G; Brandt M; Pierce S; Vaughan K; Ning J; Nogueras González GM; Patel K; Jorgensen J; Pemmaraju N; Kadia T; Konopleva M; Andreeff M; DiNardo C; Cortes J; Ward R; Craig A; Ravandi F
Haematologica; 2017 Oct; 102(10):1709-1717. PubMed ID: 28729302
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].
Zhang JL; Cao YP; Li JG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):494-503. PubMed ID: 30998160
[TBL] [Abstract][Full Text] [Related]
35. [Clinical Observation of Therapeutic Regimen Consisted of Decitabine Combined with Low-Dose IA Regimen for Myelodysplastic Syndrome-EB].
Wu D; Hao JX; Li J; Zhang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1477-1481. PubMed ID: 29070128
[TBL] [Abstract][Full Text] [Related]
36. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
Haumschild R; Kennerly-Shah J; Barbarotta L; Zeidan AM
J Oncol Pharm Pract; 2024 Jun; 30(4):721-736. PubMed ID: 38509812
[TBL] [Abstract][Full Text] [Related]
37. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
38. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
39. [Comparison of Decitabine Rigimen and Traditional Chemotherapy Regimen in Treatment of Patients with Intermediate or High-Risk Myelodysplastic Syndrome].
Zhang QP; Han YS; Wan X; Sun GY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):197-201. PubMed ID: 29397843
[TBL] [Abstract][Full Text] [Related]
40. [Comparative analysis of decitabine combined with DAG regimen and other regimens in treatment of refractory/relapsed acute myeloid leukemia].
Hao J; Wang L; Wang Y; Liu Z; Gu X; Liu J; Li L; Duan Y; Chen Y; Zhao W; Shen Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):481-5. PubMed ID: 24985167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
